💊 AbbVie off to a good start in 2025: Immunology pulls growth, obesity drug as a new opportunity!
Pharma giant AbbVie $ABBV has started this year in very solid shape. The first quarter results exceeded market expectations and point to a successful transformation of the company's portfolio after a decline in revenue from Humira (an autoimmune disease treatment).

📊 Important Q1 2025 numbers:
Adjusted EPS: $2.46 (+6.5% YoY)
GAAP EPS: $0.72 (-6.5% YoY, impacted by exceptional costs)
Revenue: $13.34 billion (+8.4% YoY)
Gross margin: 84.1%
Operating margin: 42.3%

🔬 Portfolio growth drivers
💥 Immunology ($6.26 billion, +16.6% y/y):
Skyrizi and Rinvoq +57,2 %. A pair of drugs that is gradually replacing Humira and doing better than markets expected. Revenue from Humira , on the other hand, fell by more than half, exactly as expected.

🧠 Neurology ($2.28 billion, +16.1% y/y):
The drivers are Vraylar, Botox Therapeutic, Ubrelvy a Qulipta. This growth shows that diversification outside traditional areas is paying off.

🧬 Oncology (USD 1.63 billion, +5.8% y/y):
Steady growth, strong performance at Venclexta a Elaherewhich are building a position in gynecological cancer.

💉 Aesthetics (-11.7% y/y):
One of the few weaker parts of the report - a decline in sales at Botox Cosmetic a Juvederm due to weaker demand.

📈 Outlook for the full year 2025
The company raised full-year adjusted earnings guidance to $12.09-12.29 per share, confirming confidence in its continued growth trajectory.

🚀 Strategic Actions and Innovation
Rinvoq approved for treatment in the EU
Elahere shows strong Phase 3 data in ovarian cancer trial
Partnership with Xilio Therapeutics (immunotherapy)
Entering the obesity treatment market: collaboration with Gubra to develop amylin analogue ABBV-295
Approval of new antibiotic Emblaveo for complicated abdominal infections

🧭 Leadership changes
The current CEO will take over from July 2025 CEO Robert A. Michael as Chairman of the Board. He will thus succeed Richard A. Gonzalezwho has led the company since its inception in 2013.

AbbVie has had a very strong quarter, confirming that the transition from drug Humira to a new generation of immunologic drugs is well underway. The fields of immunology, neurology and oncology are growing at double-digit rates. In addition, the portfolio is expanding into new areas - such as obesity treatment, which has made AbbVie makes AbbVi an even more interesting bet for long-term investors.

What do you think of this pharmaceutical giant? Does anyone have shares of this company in their portfolio, or are you following other players?